TABLE 4.
Bone markers of resorption and deposition from baseline to 12 mo postpartum in women taking calcium supplements or placebo1
| Visit 1 (baseline; 16 wk of pregnancy) | Visit 2 (26 wk of pregnancy) | Visit 3 (36 wk of pregnancy) | Visit 4 (4 mo postpartum) | Visit 5 (12 mo postpartum) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Calcium (n = 32) | Placebo (n = 32) | Calcium (n = 28) | Placebo (n = 29) | Calcium (n = 26) | Placebo (n = 27) | Calcium (n = 22) | Placebo (n = 23) | Calcium (n = 15) | Placebo (n = 15) | |
| Osteocalcin, ng/mL | 6.9 ± 1.9 | 7.7 ± 2.0 | 6.9 ± 1.7 | 7.1 ± 2.5 | 9.1 ± 3.1 | 9.3 ± 3.5 | 14.2 ± 2.5 | 17.3 ± 3.9 | 11.3 ± 3.6 | 13.9 ± 3.4 |
| CICP, pmol/L | 6.4 ± 1.9 | 6.67 ± 2.2 | 7.2 ± 2.7 | 9.1 ± 5.0 | 9.7 ± 2.8 | 13.9 ± 13.8 | 9.9 ± 3.3 | 16.5 ± 14.4 | 8.8 ± 2.9 | 10.3 ± 7.8 |
| CTx, nM BCE/L | 0.2 ± 0.1 | 0.3 ± 0.5 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.4 ± 0.3 | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.5 ± 0.3 | 0.2 ± 0.12 | 0.3 ± 0.22 |
| Osteoprotegerin, pmol/L | 9.0 ± 3.8 | 10.1 ± 5.9 | 12.9 ± 5.4 | 13.4 ± 7.5 | 17.4 ± 6.7 | 20.2 ± 14.5 | 6.9 ± 1.9 | 5.9 ± 3.2 | 6.9 ± 3.9 | 4.9 ± 2.7 |
1
Values are means ± SDs. Statistical analysis: group (calcium compared with placebo) × time effects reported from baseline (visit 1) to 12 mo postpartum (visit 5) using general linear models. Calcium: 1000 mg Ca/d from 16 wk of pregnancy to delivery. Placebo: placebo capsules daily from 16 wk of pregnancy to delivery. BCE, bone collagen equivalent; CICP, C-terminal propeptide of type 1 procollagen; CTx, cross-linked C-terminal telopeptide of type 1 collagen.
2
P = 0.044, group × time effect from baseline to 12 mo postpartum.